DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

JOURNAL OF DRUG EDUCATION, published by SAGE Publications Inc, serves as a vital platform for disseminating research and scholarly articles in the fields of health education, medicine, and mental health, focusing on drug-related issues. With its history dating back to 1972 and an ongoing publication cycle through 2024, the journal aims to enrich professional practice and inform policy-making through rigorous research. Although it does not currently operate under an Open Access model, the journal holds respectable rankings, finding itself in the third quartile across multiple categories including Health (Social Science), Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, as per the 2023 metrics. This evaluation signifies its contribution to the discourse surrounding drug education and public health albeit within a competitive landscape. Scholars, researchers, and practitioners in the field are encouraged to engage with and contribute to this important dialogue addressing drug-related challenges in contemporary society.

Journal of Substance Use & Addiction Treatment is a premier scholarly publication dedicated to advancing the understanding and treatment of substance use disorders and addictive behaviors. Published by Elsevier Science Inc, this journal serves as a vital platform for researchers, clinicians, and students in the fields of psychology, psychiatry, public health, and addiction studies. With its commitment to Open Access, the journal facilitates wide dissemination of cutting-edge research, enabling practitioners and policymakers to access critical findings that inform treatment approaches and public health strategies. As an essential resource in addiction treatment and research, the Journal of Substance Use & Addiction Treatment aims to foster interdisciplinary collaboration and innovation, ultimately improving outcomes for individuals affected by addiction.

JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.

The Journal of Social Work Practice in the Addictions is a pivotal publication in the field of social work, dedicated to addressing the multifaceted challenges of addiction through rigorous research and practice. Published by Routledge Journals, Taylor & Francis Ltd, this journal has been a valuable resource since its inception in 2001 and continues to provide vital insights as it converges towards 2024. With a focus on empirical studies, theoretical advancements, and innovative practice approaches, it serves professionals and researchers alike who are engaged in the health and social sciences. Holding a respectable Q3 quartile ranking in both Health (Social Science) and Rehabilitation and a Q4 ranking in Social Work, it emphasizes the importance of interdisciplinary collaboration in tackling issues of addiction. The journal does not currently offer open access, ensuring exclusive dissemination to its dedicated readership, which includes practitioners, scholars, and students committed to improving outcomes for individuals affected by substance use disorders. As an essential platform within the community, it fosters knowledge exchange and supports evidence-based practice, thereby enhancing the field’s collective understanding of addiction-related challenges.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.